Pession Andrea, Masetti Riccardo, Di Leo Corinne, Franzoni Monica, Prete Arcangelo
Pediatric Oncology and Hematology Lalla Seràgnoli Unit, University of Bologna, Bologna, Italy.
Pediatr Rep. 2011 Jun 22;3 Suppl 2(Suppl 2):e12. doi: 10.4081/pr.2011.s2.e12.
Even if the overall survival of children with cancer is significantly improved over these decades, the cure rate of high-risk pediatric solid tumors such as neuroblastoma, Ewing's sarcoma family tumors or rhabdomiosarcoma remain challenging. Autologous hematopoietic stem cell transplantation (HSCT) allows chemotherapy dose intensification beyond marrow tolerance and has become a fundamental tool in the multimodal therapeutical approach of these patients. Anyway this procedure does not allow to these children an event-free survival approaching more than 50% at 5 years. New concepts of allogeneic HSCT and in particular HLA-mismatched HSCT for high risk solid tumors do not rely on escalation of chemotherapy intensity and tumor load reduction but rather on a graft-versus-tumor effect. We here report an experimental study design of HLA-mismatched HSCT for the treatment of pediatric solid tumors and the inherent preliminary results.
尽管在过去几十年里，癌症患儿的总体生存率有了显著提高，但神经母细胞瘤、尤因肉瘤家族肿瘤或横纹肌肉瘤等高风险小儿实体瘤的治愈率仍然具有挑战性。自体造血干细胞移植（HSCT）能够使化疗剂量强化至超过骨髓耐受程度，已成为这些患者多模式治疗方法中的一项基本手段。然而，该方法并不能使这些患儿的5年无事件生存率超过50%。异基因HSCT的新概念，特别是针对高风险实体瘤的HLA配型不合HSCT，并不依赖于化疗强度的提升和肿瘤负荷的降低，而是依赖于移植物抗肿瘤效应。我们在此报告一项针对小儿实体瘤治疗的HLA配型不合HSCT的实验性研究设计及其初步结果。
